Achaogen: Achaogen, Inc.'s Bankruptcy Sale To Xuanzhu Biopharmaceutical Ltd.

Hogan Lovells represented biopharmaceutical company Achaogen, Inc. in its Chapter 11 bankruptcy. Achaogen was best known for its development of ZEMDRI® (plazomicin), an anti-infective drug approved to treat drug-resistant cUTI. Following a sale of certain of Achaogen's plazomicin rights in July 2019 (a sale also handled by Hogan Lovells), Achaogen this month consummated a sale [...]